Youtor
Interrogate tumorimmune interactions in AML patients receiving immune checkpoint inhibitor
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=WNo2E4XejmE
Presented By: • Vikram Devgan, PhD, MBA • Dr. Chen Zhao • Speaker Biography: • Dr. Devgan is the Senior Director of Spatial Genomics Business Unit at NanoString Technologies. He received his Ph.D. in molecular biology and conducted post-doctoral research at Harvard Medical School before moving to the biotechnology industry. He received his MBA from the University of Wurzburg in Germany and has spent many years as a scientist in developing new technologies and products clinical and translational research. • Dr. Chen Zhao is a medical oncologist, immunologist, and physician-scientist focusing on tumor immunology and immunotherapy. He specializes in developing novel immunotherapeutics and using advanced tissue imaging techniques and spatial-transcriptomic analysis to understand the three-way interactions among tumor cells, the immune system, and the microbiota in the tumor microenvironment over the course of cancer initiation, progression, and therapeutic response. • Webinar: • Interrogate tumor-immune interactions in AML patients receiving immune checkpoint inhibitor • Webinar Abstract: • Introducing Nanostring’s latest spatial platform, CosMx Spatial Molecular Imager (SMI). Offering high-plex, multiomic in situ analysis with single-cell to subcellular resolution in intact Formalin-Fixed Paraffin-Embedded (FFPE) and fresh frozen tissue sample. Learn how CosMx SMI advances spatially resolved single cell applications including cell atlasing, cellular neighborhoods analysis, biomarker discovery and subcellular localization analysis. • • In today’s talk Dr. Chen Zhao will elaborate on how his lab spatially resolved the tumor-immune interactions in the bone marrow microenvironment to gain a deeper understanding of the tumor-immune microenvironment in R-AML during combination ICI treatment. • • Relapsed or refractory Acute Myeloid Leukemia (R-AML) is a deadly disease with an inadequate response rate to current treatments. Recent advances in immunotherapy shed light on R-AML, and several clinical trials have shown promising potential for combining immune checkpoint inhibitors (ICIs) with hypomethylating agents. Comprehending the tumor-immune microenvironment in R-AML during combination ICI treatment is urgently needed for developing better therapeutics and stratifying treatment strategies. • • To dissect the tumor-immune interactions in the bone marrow microenvironment, Dr. Zhao’s team employed NanoString GeoMx Digital Spatial Profiler (DSP), CosMx SMI, and performed a spatial-transcriptomic analysis of patients with R-AML who received pembrolizumab and decitabine. Comparing the transcriptomic profiles and TCR clonalities of tumor-interacting T cells, bystander T cells, and other cells at baseline, post-pembrolizumab treatment, and post-decitabine, led to identification of R-AML’s suppressive immune microenvironment and immune cells’ responses to ICI and hypomethylating agent. • • The spatial-transcriptomic profiles of T cells, stromal cells, and leukemia cells in patients with R-AML were obtained at different treatment points. The TCR-specific probes were able to track T cell clonal changes during treatments. R-AML harbored a complex tumor immune microenvironment and diverse T cell clonality. • • LabRoots on Social: • Facebook: / labrootsinc • Twitter: / labroots • LinkedIn: / labroots • Instagram: / labrootsinc • Pinterest: / labroots • SnapChat: labroots_inc
#############################
